Flow cytometry application

Like Us

Flow Cytometry Application

  • Cell biology: apoptosis, sorting of cells in certain cell cycle stage, cell cycle-related DNA, RNA, antigen, cancer gene, karyotype analysis, X and Y chromosome purification
  • Oncology: DNA ploid content analysis which is an indicator of detecting benign tumor and malignant tumor, for recent years DNA ploid analysis has been applied in detection of leukemia, adenolymphoma, lung cancer, bladder cancer, prostatic cancer. Monoclonal antibodies can be applied to eliminate tumor cells in blood.
  • Immunology: relationship between cell cycle or DNA ploid and cell surface receptors and antigen expression. Cell sorting of active immune cell and purification. Analysis of relationship between lymphocyte subpopulation and diseases. Immunodeficiency diseases and HIV diagnosis. Immune assay after organ transplantation.
  • Hematology: classification and sorting of blood cells, differentiation of hematopoietic cells, quantification of various enzymes in blood, such as peroxidase, acid non-specific alpha-naphthol acetate esterase (ANAE) etc. Double staining with NBT and DNA can illustrate relationship between differentiation of leukemia cells and cell cycle.

e.g. CD3: A normal person has a significant proportion of CD3-positive lymphocytes. In the patient with leukemia, staining for CD3 is absent.
CD20 (CD20 recobinant protein141-184, 213-297, CD20 primary antibody conjugated to FITC): In the leukemia patient there are a large number of cells staining positive for CD20. In the healthy person only a few stain positive.
HLA-DR: The leukemia patient is HLA-DR-positive. In the normal person only a small number of cells stain positive.
Being CD3-negative, CD20-positive and HLA-DR-positive, a clinician could
diagnose with certainty that this patient is suffering from a B cell lineage
leukemia or lymphoma. The precise classification of disease may be
determined using further antibodies.

  • Pharmacology: analysis distribution of drug in cells, mechanisms of drug, new drug screening.